This product comprises a polyclonal population of A-549 human lung adenocarcinoma cells in which the ARFIP1 gene has been functionally disrupted by CRISPR/Cas9-mediated gene editing. The resulting polyclonal knockout cells retain the heterogeneous genetic background of the parental line while carrying a loss-of-function modification at the ARFIP1 locus, enabling researchers to study the collective impact of ARFIP1 deficiency on cellular processes without clonal selection bias. The polyclonal format provides a robust model for investigating ARFIP1-dependent phenotypes in a context that more closely mimics the diversity of a natural tumor microenvironment.
A-549 cells are a well-established epithelial cell line derived from a human lung carcinoma, widely used as a model for lung adenocarcinoma biology. These cells harbor a KRAS G12S mutation and express wild-type TP53, making them particularly relevant for studying RAS-driven oncogenic signaling and alveolar epithelial function. The adherent, epithelial morphology of A-549 cells supports a broad range of cell-based assays, from high-resolution imaging to biochemical analyses, and their well-characterized growth properties facilitate reproducible experimental designs.
ARFIP1 encodes a regulator of ADP-ribosylation factor (ARF) GTPases, which are central coordinators of vesicular trafficking at the Golgi apparatus and endosomal compartments. ARFIP1 functions downstream of ARF1 activation, interacting directly with ARF1 and ARF3, and is implicated in the formation of coatomer (COPI)-coated vesicles. Through these interactions, ARFIP1 modulates Golgi organization, phospholipase D activity, and actin cytoskeleton dynamics. Knockout of ARFIP1 disrupts ARF1-mediated COPI vesicle biogenesis, leading to alterations in Golgi morphology and perturbations in secretory and endocytic recycling pathways. Additionally, ARFIP1 is positioned within a signaling network that includes EGFR as an upstream activator and GGA1 as a downstream adaptor, linking growth factor signaling to membrane trafficking.
In the context of A-549 lung adenocarcinoma cells, loss of ARFIP1 may profoundly affect tumor-relevant processes such as cell proliferation, migration, and secretion of signaling proteins. Given the reliance of KRAS-mutant cancer cells on efficient vesicular trafficking for sustained growth and survival, ARFIP1 knockout provides a targeted approach to dissect the intersection between oncogenic signaling and membrane dynamics. This model is particularly valuable for studying how Golgi disorganization and defective protein secretion influence the malignant phenotype and response to therapeutic agents, offering insights into membrane trafficking disorders and their role in cancer biology.
This polyclonal ARFIP1 knockout cell population is ideal for a variety of experimental applications, including investigation of Golgi architecture by immunofluorescence, quantification of secreted factors via ELISA-based assays, and assessment of cell migration and invasion. It is also suited for drug sensitivity profiling to identify compounds that preferentially target cells with compromised vesicular trafficking. Researchers can employ western blotting and RT-qPCR to confirm loss of ARFIP1 expression and monitor downstream effectors, while functional assays enable dissection of ARFIP1-dependent pathways. For additional information or customized product requests, please contact Ascent Research.
